Genprex, Inc.

Company Overview

Business Model: Genprex, Inc. is a clinical stage gene therapy company focused on developing gene-based therapies for large patient populations with unmet medical needs. Its oncology platform utilizes a systemic, non-viral ONCOPREX® Delivery System to deliver tumor suppressor gene-expressing plasmids intravenously to cancer cells. The diabetes technology aims to treat Type 1 diabetes by transforming pancreatic alpha cells into functional beta-like cells that produce insulin, and Type 2 diabetes by replenishing and rejuvenating exhausted beta cells.

Market Position: Genprex, Inc. operates in the intensely competitive biotechnology and pharmaceutical industries. Its oncology program targets lung cancer, which was the leading cause of cancer deaths worldwide in 2023 and accounts for approximately one in five cancer deaths in the U.S. Non-small cell lung cancer (NSCLC) represents about 82% of lung cancers, and small cell lung cancer (SCLC) about 14%. The TUSC2 protein, central to Genprex, Inc.'s REQORSA therapy, is reduced or absent in approximately 82% of NSCLCs and 100% of SCLCs. REQORSA is believed to be the first systemic gene therapy used for cancer in humans. In diabetes, the company addresses a global market of approximately 537 million adults with diabetes in 2021, projected to rise to 783 million by 2045.

Recent Strategic Developments:

• Reverse Stock Split: A one-for-forty (1:40) reverse stock split of Common Stock became effective on February 2, 2024.
• ATM Offering Program: Genprex, Inc. entered an At The Market (“ATM”) Offering Agreement with H.C. Wainwright & Co., LLC on December 13, 2023. During 2024, 7,684,953 shares were sold for net proceeds of approximately $6.1 million. From January 1, 2025, through the filing date, an additional 13,278,666 shares were sold for net proceeds totaling $6,028,104.
• Diabetes Program Separation: In September 2024, Genprex, Inc. announced plans to transfer its diabetes clinical development program and assets into a new, initially wholly-owned subsidiary. On February 18, 2025, Convergen Biotech, Inc. was formed as a wholly-owned subsidiary to focus on developing and commercializing GPX-002, while Genprex, Inc. retains its oncology assets.
• The University of Texas MD Anderson Cancer Center Collaboration: In August 2022, a three-year sponsored research agreement was initiated for preclinical studies of TUSC2 and other tumor suppressor genes, amended in June 2024 to extend by 6 months and adjust the budget.
• University of Pittsburgh Licenses/Collaborations: Genprex, Inc. exclusively licensed multiple technologies from the University of Pittsburgh for Type 1 and Type 2 diabetes gene therapy. In October 2023, a one-year extension was made to a sponsored research agreement for GPX-002. On February 17, 2025, an amended and restated Exclusive License Agreement was entered with the University of Pittsburgh, consolidating prior agreements and covering gene therapy for Type 1 and Type 2 diabetes.
• University of Michigan Collaboration: In October 2024, a sponsored research agreement was entered with the University of Michigan Rogel Cancer Center to study TUSC2 in combination with ALK-inhibitors. In November 2024, an exclusive license agreement was secured for patent rights relating to REQORSA in combination with ALK-inhibitors for ALK-EML4 positive translocated lung cancer.

Geographic Footprint: Genprex, Inc.'s primary executive offices are located in Austin, Texas. Clinical trials (Acclaim-1, Acclaim-3) are expected to enroll patients at approximately 10-15 U.S. clinical sites. The company holds worldwide exclusive licenses for its oncology and diabetes technologies from The University of Texas MD Anderson Cancer Center, University of Pittsburgh, and University of Michigan.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: N/A
• Operating Margin: N/A
• Net Margin: N/A

Investment in Growth:

• R&D Expenditure: $10,535,446 (2024), $17,616,605 (2023)
• Capital Expenditures: Net cash provided by (used in) investing activities was $1,166 (2024) and $(71,214) (2023).
• Strategic Investments:
  • The University of Texas MD Anderson Cancer Center License: Includes milestone payments up to $6,150,000, annual maintenance fees, and low single to low double digit royalty payments.
  • University of Michigan License Agreement: Includes an initial license issue fee, running low single digit percentage royalties, fixed cash minimum annual royalties, a tiered double digit percentage share of non-royalty sublicense income, and potential clinical milestone payments up to approximately $350,000.
  • New University of Pittsburgh License Agreement: Includes an initial license fee, annual maintenance fees, running low single digit percentage royalties, fixed cash minimum annual royalties, a low double digit percentage share of non-royalty sublicense income, and milestone payments up to approximately $4,825,000.

Business Segment Analysis

The company manages its operations as a single segment, focusing on the discovery and development of gene therapies for unmet medical needs. Performance is assessed based on net loss.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: No share repurchases were mentioned.
• Dividend Payments: No dividend payments have ever been declared or paid, and none are anticipated in the foreseeable future.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31):

• Cash and Equivalents: $1,601,660 (2024), $6,737,629 (2023)
• Total Debt: $0 (2024), $0 (2023)
• Net Cash Position: $1,601,660 (2024)
• Accumulated Deficit: $(154,799,443) (2024), $(133,688,280) (2023)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable as no debt is reported.

Cash Flow Generation:

• Operating Cash Flow: $(17,149,088) (2024), $(24,738,603) (2023)
• Free Cash Flow: $(17,150,254) (2024), $(24,667,389) (2023) (Calculated as Operating Cash Flow minus Net cash provided by (used in) investing activities)
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Genprex, Inc. invests substantially in manufacturing through third-party contract development and manufacturing organizations (CDMOs). REQORSA, an immunogene therapy, utilizes a TUSC2 DNA plasmid encapsulated by non-viral DOTAP cholesterol lipoplexes (ONCOPREX Delivery System). This system is scalable at cGMP and allows for storage of approximately 12 to 18 months. Tech transfer from The University of Texas MD Anderson Cancer Center to CDMOs and scale-up of clinical grade manufacturing to cGMP have been achieved. GPX-002 for diabetes involves AAV vector delivery of Pdx1 and MafA genes into the pancreatic duct. A strategic collaboration with a CDMO is researching a non-viral lipid nanoparticle delivery system for diabetes gene therapy for potential re-dosing.

Supply Chain Architecture: Key Suppliers & Partners:

• Contract Development and Manufacturing Organizations (CDMOs): Genprex, Inc. relies on third-party CDMOs for the manufacture of GMP grade materials for its clinical programs. The growth in the gene therapy sector increases demand for CDMO services, potentially impacting production scheduling. A previous three-year development services agreement with a CDMO was terminated by mutual agreement in June 2024, with the CDMO agreeing to return $1.5 million.
• Academic Institutions (Licensors): The University of Texas MD Anderson Cancer Center, University of Pittsburgh, and University of Michigan are key partners providing exclusive worldwide licenses for the company's core technologies.

Facility Network:

• Manufacturing: Relies on third-party CDMOs for cGMP manufacturing.
• Research & Development: Conducts R&D through internal efforts and sponsored research agreements with academic institutions like The University of Texas MD Anderson Cancer Center, University of Pittsburgh, and University of Michigan Rogel Cancer Center.
• Distribution: Not applicable as the company has no commercial products.

Operational Metrics:

• In preclinical studies, REQORSA treatment demonstrated TUSC2 uptake in tumor cells 10 to 33 times higher than in normal cells.
• Biopsies in three NSCLC patients showed major increases in TUSC2 protein expression in tumor cells one day after REQORSA administration.

Market Access & Customer Relationships

Go-to-Market Strategy: Genprex, Inc. currently has no sales, marketing, or distribution experience. The company anticipates needing to invest significant resources or partner with third parties for future commercialization efforts.

Customer Portfolio:

• Enterprise Customers: Not applicable as the company is clinical stage with no commercial products.
• Customer Concentration: Not applicable.

Geographic Revenue Distribution: Genprex, Inc. has never generated revenue from product sales.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industries are intensely competitive, characterized by rapid technological change and a strong emphasis on intellectual property. The gene therapy sector is experiencing significant growth, leading to increased demand for specialized CDMO services.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Lung Cancer:
  • Chemotherapies: Cisplatin, carboplatin, docetaxel, pemetrexed.
  • Targeted Therapies: Tarceva, Iressa, Gilotrif, Tagrisse.
  • Immunotherapies: Checkpoint inhibitors, CAR/CAR T cells, oncolytic virus-based technology.
• Diabetes:
  • Insulin and Insulin Analogs: Standard treatments.
  • Monitoring & Delivery: Continuous glucose monitoring, insulin pens/pumps.
  • Preventative Therapeutics: Various pharmaceutical interventions.
  • Cellular Therapies: Allogeneic beta cells.

Emerging Competitive Threats: The rapidly evolving gene therapy sector and advancements in oncology and diabetes treatments pose continuous competitive threats.

Competitive Response Strategy: Genprex, Inc.'s strategy is to develop REQORSA in combination with currently approved therapies. The company believes its multimodal activity can block emerging bypass pathways and reduce drug resistance, offering a differentiated approach.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: Unstable market and economic conditions may adversely affect Genprex, Inc.'s business, financial condition, and stock price. Technology Disruption: The company operates in a rapidly changing technological landscape, facing risks of obsolescence from new entrants, disruptive technologies, or alternative solutions. Customer Concentration: Not applicable as the company has no commercial products or customers.

Operational & Execution Risks

Supply Chain Vulnerabilities: Genprex, Inc. is dependent on third-party suppliers and manufacturers (CDMOs) for key ingredients, raw materials, products, and components. The increasing demand for CDMO services in gene therapy could impact production scheduling and costs. Geographic Concentration: Primary operations are in the U.S., with clinical trials expected across U.S. sites. Capacity Constraints: Reliance on third-party manufacturing introduces potential capacity constraints.

Financial & Regulatory Risks

Market & Financial Risks:

• Funding Risk: Substantial additional funding is required to continue operations and advance clinical programs, and such funding may not be available on acceptable terms or at all.
• Going Concern: Recurring losses from operations raise substantial doubt about the company's ability to continue as a going concern. Cash and cash equivalents of approximately $1.6 million at December 31, 2024, are expected to be insufficient to meet operating and capital requirements for at least 12 months from the filing date.
• Accumulated Deficit: The company had an accumulated deficit of approximately $154.8 million as of December 31, 2024.
• Foreign Exchange: Foreign currency fluctuations could increase operating expenses and reduce revenues, though not currently material given U.S. focus. Regulatory & Compliance Risks:
• Industry Regulation: The biopharmaceutical industry is subject to extensive and changing regulatory obligations, including FDA regulations for pharmaceutical products and biologics (gene therapies), GLPs, GCPs, IRB, and IBC review.
• Data Privacy: Data privacy and security regulations (HIPAA, HITECH) apply to the company's operations.
• Healthcare Laws: Federal Anti-Kickback Statute, False Claims Act, and Physician Payments Sunshine Act impose compliance requirements.
• Drug Pricing: The Inflation Reduction Act of 2022 authorizes CMS to negotiate drug prices and requires rebates if prices rise faster than inflation, potentially impacting future commercialization.

Geopolitical & External Risks

Geopolitical Exposure: Business interruptions from geopolitical actions (war, terrorism) or natural disasters (wildfires, floods, epidemics) are potential risks. Trade Relations: Not explicitly detailed, but trade tensions and policy changes could impact global supply chains or market access. Sanctions & Export Controls: Compliance requirements and business limitations related to sanctions and export controls are applicable.

Internal Controls: Management concluded internal controls over financial reporting were ineffective as of December 31, 2024, due to a lack of segregation of duties and insufficient depth of in-house accounting personnel for complex transactions.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Oncology (REQORSA):
  • Investment Level & Strategic Importance: REQORSA (quaratusugene ozeplasmid) is in Phase 2a/2b for NSCLC and Phase 2 for SCLC. It is considered a first-in-class systemic gene therapy for cancer.
  • Innovation Pipeline: Preclinical research is ongoing for REQORSA in ALK-positive NSCLC, NSCLC progressing after RAS inhibitors, mesotheliomas, and gliomas. The company is also researching other cancer-fighting genes like NPRL2 using the ONCOPREX Delivery System.
• Diabetes (GPX-002):
  • Investment Level & Strategic Importance: GPX-002 is in preclinical development for Type 1 and Type 2 diabetes, with a focus on transforming alpha cells into functional beta-like cells.
  • Innovation Pipeline: Research is underway for a non-viral lipid nanoparticle delivery system for diabetes gene therapy to enable potential re-dosing.

Intellectual Property Portfolio:

• Patent Strategy: Genprex, Inc. holds worldwide exclusive licenses from The University of Texas MD Anderson Cancer Center for TUSC2 and other cancer-fighting genes (12 issued patents, 12 pending applications, expiring 2025-2038). It also holds worldwide exclusive licenses from the University of Pittsburgh for diabetes technologies (1 issued patent, 10 pending applications, expiring 2035-2044), and a worldwide exclusive license from the University of Michigan for a co-owned pending patent application related to REQORSA in combination with ALK-inhibitors (expiring 2045). The company is prosecuting 8 patent applications for oncology targets and expects up to 12 years of exclusivity from first BLA approval.
• Licensing Programs: The company's business model is built on exclusive licenses from academic institutions.
• IP Litigation: No material disputes were disclosed.

Technology Partnerships:

• Strategic Alliances: The University of Texas MD Anderson Cancer Center, University of Pittsburgh, University of Michigan Rogel Cancer Center.
• Research Collaborations: ALK Positive (a non-profit patient-driven research organization).

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Ryan M. Confer assumed the President and CEO roles in May 2024 following the passing of former CEO J. Rodney Varner and continues as CFO until a successor is identified.

Board Composition: The Board of Directors is composed of four directors, divided into three classes. All directors, except Ryan M. Confer, are independent according to Nasdaq and SEC rules.

• Class I: Brent M. Longnecker (term expires 2027)
• Class II: Will R. Wilson, Jr. (term expires 2025)
• Class III: Jose Antonio Moreno Toscano (term expires 2026), Ryan Confer (term expires 2026)

Human Capital Strategy

Workforce Composition:

• Total Employees: 15 full-time employees as of March 15, 2025.
• Skill Mix: Employees are highly skilled, with many holding advanced degrees and possessing drug development experience.

Talent Management: Acquisition & Retention: Genprex, Inc. focuses on attracting and retaining talent through competitive compensation, comprehensive benefits, professional development opportunities, and a pay-for-performance philosophy. Employee Value Proposition: Not explicitly detailed beyond compensation and development.

Diversity & Development: The company is committed to fostering an environment of mutual respect and equal opportunity, valuing a diverse workforce, and supporting personal and professional growth.

Environmental & Social Impact

Environmental Commitments: Genprex, Inc. is subject to federal, state, local, and foreign environmental, health, and safety laws and regulations regarding hazardous materials and waste. No specific climate strategy, emissions targets, or renewable energy commitments were disclosed.

Supply Chain Sustainability: No specific supplier engagement or responsible sourcing programs were disclosed.

Social Impact Initiatives: No specific community investment or product impact initiatives were disclosed.

Business Cyclicality & Seasonality

Demand Patterns: No explicit seasonal trends are disclosed for Genprex, Inc.'s business. The company's operations and financial performance are sensitive to general economic downturns and unstable market conditions.

Planning & Forecasting: Not explicitly detailed.

Regulatory Environment & Compliance

Regulatory Framework:

• Industry-Specific Regulations: The U.S. Food and Drug Administration (FDA) regulates pharmaceutical products under the Federal Food, Drug, and Cosmetic Act (FDCA) and biologics (including gene therapies) under the Public Health Service Act (PHSA) via Biologics License Applications (BLAs). The Center for Biologics Evaluation and Research (CBER) regulates gene therapy products. Preclinical tests must comply with Good Laboratory Practices (GLPs), and clinical trials with Good Clinical Practices (GCPs), Institutional Review Board (IRB), and Institutional Biosafety Committee (IBC) review. The FDA recommends observing gene therapy patients for up to 15 years for delayed adverse events.
• Expedited Programs: The FDA offers expedited programs such as Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review. Orphan Drug Designation grants 7 years of market exclusivity upon first FDA approval for a rare disease.
• International Compliance: Not explicitly detailed, but the company's worldwide licenses imply potential future international regulatory considerations.

Trade & Export Controls: Not explicitly detailed beyond general compliance requirements.

Legal Proceedings: Genprex, Inc. is not aware of any material pending litigation.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The company reported a total provision for income taxes of $2,650 in 2024 and $0 in 2023.
• Net Operating Losses (NOLs): Federal net operating loss carryforwards were approximately $96.3 million as of December 31, 2024, with approximately $1.3 million expiring in 2030 and approximately $86.6 million carried forward indefinitely. Under the 2017 Tax Cuts and Jobs Act, tax losses generated after December 31, 2017, may offset no more than 80% of annual taxable income.
• Valuation Allowance: Valuation allowances of $27.6 million for 2024 and $23.4 million for 2023 have been recorded against deferred tax assets.
• Tax Credits: Federal R&D credit carryforwards of $0.7 million will begin to expire in 2037.

Insurance & Risk Transfer

Risk Management Framework: Not explicitly detailed.

• Insurance Coverage: Genprex, Inc. carries product liability insurance specifically for its clinical trials.
• Risk Transfer Mechanisms: Not explicitly detailed.